189 results on '"Wakuda, K."'
Search Results
2. 384P Prevalence of fibroblast growth factor receptor 2b (FGFR2b) protein overexpression in squamous non-small cell lung cancer (sqNSCLC)
3. MA08.08 Association of FDG-PET/CT Findings with Sufficient Amount of Tissue Samples for Gene Panel Testing in TBB/TBNA.
4. 990P Osimertinib for RT-naïve CNS metastasis of EGFR mutation-positive NSCLC: Phase II OCEAN study (LOGIK 1603/WJOG 9116L), part of the first-line cohort
5. EP16.02-005 Liquid Biopsy Detects Genomic Drivers in Non-small Cell Lung Cancer without EGFR Mutations by Single-plex Testing: WJOG13620L
6. 1025P DOcetaxel (DOC) plus RAmucirumab (RAM) with pegylated Granulocyte-colONy stimulating factor (PEG-G-CSF) for elderly patients with advanced non-small cell lung cancer (NSCLC): A phase II trial (DRAGON study: WJOG9416L)
7. 1651P Phase I study of ramucirumab in combination with irinotecan plus cisplatin in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC)
8. LBA44 Primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study
9. P76.68 The Impact of Eligibility for Anti-Angiogenic Treatment to the Prognosis of Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations
10. P19.02 Association between Number of Residual Metastases and Patterns of Progression on EGFR TKI in EGFR mutated Non-Small Cell Lung Cancer
11. DIAGNOSTIC ACCURACY OF US-GUIDED TRANSTHORACIC BIOPSY FOR PERIPHERAL THORACIC LESIONS: 275
12. P1.01-04 A Phase II Trial of Weekly Nab-Paclitaxel in the Salvage Setting for Advanced Non-Small Cell Lung Cancer: Results of NICE Salvage Study
13. P3.01-54 A Historical Comparison of Patients with Advanced NSCLC Harboring Uncommon EGFR Mutations Before and After the Approval of Afatinib in Japan
14. OA05.06 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab ± Carboplatin in Advanced/mNSCLC: Initial Results from Phase 1b TROPION-Lung04.
15. Prospective evaluation of the relationship between erlotinib concentration and efficacy in patients with non-small cell lung cancer harboring EGFR-activating mutations
16. Clinical factors associated with mutation burden in non-small cell lung cancer
17. Clinical course in patients with stage III non-small cell lung cancer and interstitial lung disease treated with chemoradiotherapy: a retrospective analysis in a single institute
18. 452P Disease progression site and subsequent therapy after progression during alectinib therapy
19. 456P Practical use of osimertinib in Japanese patients with EGFR T790M mutation positive advanced non-small-cell lung cancer
20. An evaluation of the association between molecular signature and postoperative recurrence in patients with non-small cell lung cancer
21. Dramatic response to ASP-3026 in patient with highly aggressive pulmonary inflammatory myofibroblastic tumor harboring ALK rearrangement
22. Beverage consumption and the prevalence of tooth loss in pregnant Japanese women: the Osaka Maternal and Child Health Study
23. 1646P - Clinical factors associated with mutation burden in non-small cell lung cancer
24. 1357P - Prospective evaluation of the relationship between erlotinib concentration and efficacy in patients with non-small cell lung cancer harboring EGFR-activating mutations
25. 1289PD - Clinical course in patients with stage III non-small cell lung cancer and interstitial lung disease treated with chemoradiotherapy: a retrospective analysis in a single institute
26. Phase I Clinical Trial of Ds-7423, an Oral Pi3K/Mtor Dual Inhibitor, in Japanese Patients with Advanced Solid Tumors
27. Plasma Epidermal Growth Factor Receptor Mutation Analyses in Japanese Advanced Non-Small-Cell Lung Cancer Patients Horboring Egfr Mutation By Rnase H-Dependent Pcr and Blocking Oligo Dependent Pcr Methods
28. Concurrent Genetic Alterations in Lung Cancer: a Comprehensive Genomic Profiling in a Japanese Cohort
29. 122 - An evaluation of the association between molecular signature and postoperative recurrence in patients with non-small cell lung cancer
30. 1566P - Concurrent Genetic Alterations in Lung Cancer: a Comprehensive Genomic Profiling in a Japanese Cohort
31. 460P - Phase I Clinical Trial of Ds-7423, an Oral Pi3K/Mtor Dual Inhibitor, in Japanese Patients with Advanced Solid Tumors
32. 244P - Plasma Epidermal Growth Factor Receptor Mutation Analyses in Japanese Advanced Non-Small-Cell Lung Cancer Patients Horboring Egfr Mutation By Rnase H-Dependent Pcr and Blocking Oligo Dependent Pcr Methods
33. Embryo-dependent induction of embryo receptivity in the mouse endometrium
34. The integrated control system of DHCR operations and reheating furnace for hot strip mill
35. Fat and fish intake and asthma in Japanese women: Baseline data from the Osaka Maternal and Child Health Study
36. Fish and fat intake and prevalence of allergic rhinitis in Japanese females: The Osaka maternal and child health study
37. ChemInform Abstract: FORMATION OF 1,1-DITHIODICARBOXYLIC ACID ESTERS FROM CYCLIC KETONES, CARBON DISULFIDE, AND LITHIUM METHOXIDE
38. P6:01 DRAMATIC RESPONSE TO ASP-3026 IN PATIENT WITH HIGHLY AGGRESSIVE PULMONARY INFLAMMATORY MYOFIBROBLASTIC TUMOR HARBORING ALK REARRANGEMENT
39. Prognostic Impact of Postoperative Recurrence in Patients With Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
40. Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment: a retrospective study.
41. Effect of polypharmacy on the outcomes of older patients with advanced non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors: A retrospective cohort study.
42. The efficacy and safety of anamorelin among patients with diabetes.
43. Suitability of frozen cell pellets from cytology specimens for the Amoy 9-in-1 assay in patients with non-small cell lung cancer.
44. Efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma.
45. Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
46. Concordance of ALK fusion gene-rearrangement between immunohistochemistry and next-generation sequencing.
47. Relationship between patterns of immunohistochemical conventional neuroendocrine markers and efficacy of immune check point inhibitors in patients with extensive disease small cell lung cancer.
48. Safety and efficacy of amrubicin with primary prophylactic pegfilgrastim as second-line chemotherapy in patients with small cell lung cancer.
49. A Phase 2 Single-Arm Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for the First-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L).
50. Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH study (WJOG 14720 L).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.